Mirum(US:MIRM) ZACKS·2026-02-26 02:01Core Insights - Mirum Pharmaceuticals, Inc. reported $148.93 million in revenue for Q4 2025, marking a year-over-year increase of 49.8% [1] - The earnings per share (EPS) for the same period was -$0.11, an improvement from -$0.49 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $141.27 million by 5.42%, while the EPS fell short of the consensus estimate of $0.02 by 650% [1] Financial Performance - Total product sales reached $148.93 million, slightly above the average estimate of $142.62 million from four analysts [4] - Product sales for Bile Acid Medicines were $42.55 million, closely aligning with the average estimate of $42.58 million from three analysts [4] - Livmarli product sales amounted to $106.39 million, surpassing the estimated $98.37 million from three analysts [4] Stock Performance - Shares of Mirum Pharmaceuticals have returned +8.3% over the past month, contrasting with a -0.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]